Identification of a neutralizing epitope within Antigenic domain 5 of glycoprotein B of human cytomegalovirus

Journal of Virology

Volumn 89, Issue 1, 2015, Pages 361-372

  Wiegers, Anna Katharina ^a   Sticht, Heinrich ^a   Winkler, Thomas H ^b   Britt, William J ^c   Mach, Michael ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENIC DOMAIN 5; EPITOPE; GLYCOPROTEIN B; UNCLASSIFIED DRUG; YNND EPITOPE; GLYCOPROTEIN B, SIMPLEXVIRUS; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOFLUORESCENCE; MOLECULAR EVOLUTION; MUTAGENESIS; NONHUMAN; PROTEIN ANALYSIS; VIRUS NEUTRALIZATION; VIRUS STRAIN; CYTOMEGALOVIRUS; EPITOPE MAPPING; GENETICS; HUMAN; IMMUNOLOGY; NUCLEOTIDE SEQUENCE;

HUMAN HERPESVIRUS 5;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; DNA MUTATIONAL ANALYSIS; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; HUMANS; VIRAL ENVELOPE PROTEINS;

EID: 84919460189     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02393-14     Document Type: Article

References (67)

1. Kenneson A, Cannon MJ. 2007. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253-276. http://dx.doi.org/10.1002/rmv.535.
2. Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA. 1992. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 11:93-99. http://dx.doi.org/10.1097/00006454-199202000-00007.
3. Dahle AJ, Fowler KB, Wright JD, Boppana SB, Britt WJ, Pass RF. 2000. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol 11:283-290.
4. Stratton KR, Durch JS, Lawrence RS. 2000. Vaccines for the 21st century: a tool for decisionmaking. National Academy Press, Washington, DC.
5. Fu TM, An Z, Wang D. 2014. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine 32:2525-2533. http://dx.doi.org/10.1016/j.vaccine.2014.03.057.
6. Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ, Boppana SB. 2010. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201:386-389. http://dx.doi.org/10.1086/649903.
7. Reeves M, Sinclair J. 2008. Aspects of human cytomegalovirus latency and reactivation. Curr Top Microbiol Immunol 325:297-313.
8. Fowler KB, Stagno S, Pass RF. 2003. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289:1008-1011. http://dx.doi.org/10.1001/jama.289.8.1008.
9. Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Best AM. 1995. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171:26-32. http://dx.doi.org/10.1093/infdis/171.1.26.
10. Boppana SB, Britt WJ. 1995. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 171:1115-1121. http://dx.doi.org/10.1093/infdis/171.5.1115.
11. Bia FJ, Griffith BP, Tarsio M, Hsiung GD. 1980. Vaccination for the prevention of maternal and fetal infection with guinea pig cytomegalovirus. J Infect Dis 142:732-738. http://dx.doi.org/10.1093/infdis/142.5.732.
12. Bia FJ, Miller SA, Lucia HL, Griffith BP, Tarsio M, Hsiung GD. 1984. Vaccination against transplacental cytomegalovirus transmission: vaccine reactivation and efficacy in guinea pigs. J Infect Dis 149:355-362. http://dx.doi.org/10.1093/infdis/149.3.355.
13. Klenovsek K, Weisel F, Schneider A, Appelt U, Jonjic S, Messerle M, Bradel-Tretheway B, Winkler TH, Mach M. 2007. Protection from CMVinfection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110:3472-3479. http://dx.doi.org/10.1182/blood-2007-06-095414.
14. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, Dargan DJ, McGeoch DJ, Gatherer D, Emery VC, Griffiths PD, Sinzger C, McSharry BP, Wilkinson GW, Davison AJ. 2004. Genetic content of wild-type human cytomegalovirus. J Gen Virol 85:1301-1312. http://dx.doi.org/10.1099/vir.0.79888-0.
15. Van Damme E, Van Loock M. 2014. Functional annotation of human cytomegalovirus gene products: an update. Front Microbiol 5:218. http://dx.doi.org/10.3389/fmicb.2014.00218.
16. Mach M, Wiegers A, Spindler N, Winkler T. 2013. Protective humoral immunity, p 215-231. In Reddehase M (ed), Cytomegaloviruses: from molecular pathogenesis to intervention. Caister Academic Press, Norfolk, United Kingdom.
17. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC. 2006. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol 80:710-722. http://dx.doi.org/10.1128/JVI.80.2.710-722.2006.
18. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, Wagner M, Gallina A, Milanesi G, Koszinowski U, Baldanti F, Gerna G. 2004. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78:10023-10033. http://dx.doi.org/10.1128/JVI.78.18.10023-10033.2004.
19. Wang D, Shenk T. 2005. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102:18153-18158. http://dx.doi.org/10.1073/pnas.0509201102.
20. Vanarsdall AL, Ryckman BJ, Chase MC, Johnson DC. 2008. Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans. J Virol 82:11837-11850. http://dx.doi.org/10.1128/JVI.01623-08.
21. Lopper M, Compton T. 2004. Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion. J Virol 78: 8333-8341. http://dx.doi.org/10.1128/JVI.78.15.8333-8341.2004.
22. Schoppel K, Kropff B, Schmidt C, Vornhagen R, Mach M. 1997. The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J Infect Dis 175:533-544. http://dx.doi.org/10.1093/infdis/175.3.533.
23. Marshall GS, Rabalais GP, Stout GG, Waldeyer SL. 1992. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis 165:381-384. http://dx.doi.org/10.1093/infdis/165.2.381.
24. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. 1990. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64:1079-1085.
25. Gerna G, Sarasini A, Patrone M, Percivalle E, Fiorina L, Campanini G, Gallina A, Baldanti F, Revello MG. 2008. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 89:853-865. http://dx.doi.org/10.1099/vir.0.83523-0.
26. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A. 2010. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84:1005-1013. http://dx.doi.org/10.1128/JVI.01809-09.
27. Potzsch S, Spindler N, Wiegers AK, Fisch T, Rucker P, Sticht H, Grieb N, Baroti T, Weisel F, Stamminger T, Martin-Parras L, Mach M, Winkler TH. 2011. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 7:e1002172. http://dx.doi.org/10.1371/journal.ppat.1002172.
28. Zydek M, Petitt M, Fang-Hoover J, Adler B, Kauvar LM, Pereira L, Tabata T. 2014. HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex. Viruses 6:1346-1364. http://dx.doi.org/10.3390/v6031346.
29. Chatterjee A, Harrison CJ, Britt WJ, Bewtra C. 2001. Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis 183:1547-1553. http://dx.doi.org/10.1086/320714.
30. Bratcher DF, Bourne N, Bravo FJ, Schleiss MR, Slaoui M, Myers MG, Bernstein DI. 1995. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis 172:944-950. http://dx.doi.org/10.1093/infdis/172.4.944.
31. Cekinovic D, Golemac M, Pugel EP, Tomac J, Cicin-Sain L, Slavuljica I, Bradford R, Misch S, Winkler TH, Mach M, Britt WJ, Jonjic S. 2008. Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J Virol 82:12172-12180. http://dx.doi.org/10.1128/JVI.01214-08.
32. Rieder F, Steininger C. 2014. Cytomegalovirus vaccine: phase II clinical trial results. Clin Microbiol Infect 20(Suppl 5):S95-S102. http://dx.doi.org/10.1111/1469-0691.12449.
33. Plotkin SA, Plachter B. 2013. Cytomegalovirus vaccine: on the way to the future?, p 424-449. In Reddehase M (ed), Cytomegaloviruses: from molecular pathogenesis to intervention. Caister Academic Press, Norfolk, United Kingdom.
34. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G. 2009. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360:1191-1199. http://dx.doi.org/10.1056/NEJMoa0804749.
35. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK. 2011. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377:1256-1263. http://dx.doi.org/10.1016/S0140-6736(11)60136-0.
36. Yue Y, Wang Z, Abel K, Li J, Strelow L, Mandarino A, Eberhardt MK, Schmidt KA, Diamond DJ, Barry PA. 2008. Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Med Microbiol Immunol 197:117-123. http://dx.doi.org/10.1007/s00430-008-0074-5.
37. Abel K, Martinez J, Yue Y, Lacey SF, Wang Z, Strelow L, Dasgupta A, Li Z, Schmidt KA, Oxford KL, Assaf B, Longmate JA, Diamond DJ, Barry PA. 2011. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. J Virol 85:2878-2890. http://dx.doi.org/10.1128/JVI.00883-10.
38. Schleiss MR. 2013. Developing a vaccine against congenital cytomegalovirus (CMV) infection: what have we learned from animal models? Where should we go next?. Future Virol 8:1161-1182. http://dx.doi.org/10.2217/fvl.13.106.
39. Spindler N, Rucker P, Potzsch S, Diestel U, Sticht H, Martin-Parras L, Winkler TH, Mach M. 2013. Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus. J Virol 87:8927-8939. http://dx.doi.org/10.1128/JVI.00434-13.
40. Sharma S, Wisner TW, Johnson DC, Heldwein EE. 2013. HCMV gB shares structural and functional properties with gB proteins from other herpesviruses. Virology 435:239-249. http://dx.doi.org/10.1016/j.virol.2012.09.024.
41. Cairns TM, Fontana J, Huang ZY, Whitbeck JC, Atanasiu D, Rao S, Shelly SS, Lou H, Ponce de Leon M, Steven AC, Eisenberg RJ, Cohen GH. 2014. Mechanism of neutralization of herpes simplex virus by antibodies directed at the fusion domain of glycoprotein B. J Virol 88:2677-2689. http://dx.doi.org/10.1128/JVI.03200-13.
42. Scrivano L, Sinzger C, Nitschko H, Koszinowski UH, Adler B. 2011. HCMV spread and cell tropism are determined by distinct virus populations. PLoS Pathog 7:e1001256. http://dx.doi.org/10.1371/journal.ppat.1001256.
43. Andreoni M, Faircloth M, Vugler L, Britt WJ. 1989. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods 23:157-167. http://dx.doi.org/10.1016/0166-0934(89)90129-8.
44. Meyer H, Masuho Y, Mach M. 1990. The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. J Gen Virol 71:2443-2450. http://dx.doi.org/10.1099/0022-1317-71-10-2443.
45. Tischer BK, Smith GA, Osterrieder N. 2010. En passant mutagenesis: a two step markerless red recombination system. Methods Mol Biol (Clifton, NJ) 634:421-430. http://dx.doi.org/10.1007/978-1-60761-652-8_30.
46. Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, Harrison SC. 2006. Crystal structure of glycoprotein B from herpes simplex virus 1. Science (New York, NY) 313:217-220. http://dx.doi.org/10.1126/science.1126548.
47. Sharon J, Rynkiewicz MJ, Lu Z, Yang CY. 2014. Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics. Immunology 142:1-23. http://dx.doi.org/10.1111/imm.12213.
48. Ramaraj T, Angel T, Dratz EA, Jesaitis AJ, Mumey B. 2012. Antigenantibody interface properties: composition, residue interactions, and features of 53 non-redundant structures. Biochim Biophys Acta 1824:520-532. http://dx.doi.org/10.1016/j.bbapap.2011.12.007.
49. Bogan AA, Thorn KS. 1998. Anatomy of hot spots in protein interfaces. J Mol Biol 280:1-9. http://dx.doi.org/10.1006/jmbi.1998.1843.
50. Kaverin NV, Rudneva IA, Govorkova EA, Timofeeva TA, Shilov AA, Kochergin-Nikitsky KS, Krylov PS, Webster RG. 2007. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 81:12911-12917. http://dx.doi.org/10.1128/JVI.01522-07.
51. Prabakaran M, He F, Meng T, Madhan S, Yunrui T, Jia Q, Kwang J. 2010. Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J Virol 84:11822-11830. http://dx.doi.org/10.1128/JVI.00891-10.
52. Guo D, Shi X, Arledge KC, Song D, Jiang L, Fu L, Gong X, Zhang S, Wang X, Zhang L. 2012. A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01. J Biol Chem 287:43170-43179. http://dx.doi.org/10.1074/jbc.M112.399402.
53. Highlander SL, Cai WH, Person S, Levine M, Glorioso JC. 1988. Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration. J Virol 62:1881-1888.
54. Kousoulas KG, Huo B, Pereira L. 1988. Antibody-resistant mutations in cross-reactive and type-specific epitopes of herpes simplex virus 1 glycoprotein B map in separate domains. Virology 166:423-431. http://dx.doi.org/10.1016/0042-6822(88)90513-2.
55. Pereira L, Ali M, Kousoulas K, Huo B, Banks T. 1989. Domain structure of herpes simplex virus 1 glycoprotein B: neutralizing epitopes map in regions of continuous and discontinuous residues. Virology 172:11-24. http://dx.doi.org/10.1016/0042-6822(89)90102-5.
56. Bender FC, Samanta M, Heldwein EE, de Leon MP, Bilman E, Lou H, Whitbeck JC, Eisenberg RJ, Cohen GH. 2007. Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions. J Virol 81:3827-3841. http://dx.doi.org/10.1128/JVI.02710-06.
57. Feire AL, Koss H, Compton T. 2004. Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrinlike domain. Proc Natl Acad Sci USA 101:15470-15475. http://dx.doi.org/10.1073/pnas.0406821101.
58. Soroceanu L, Akhavan A, Cobbs CS. 2008. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 455:391-395. http://dx.doi.org/10.1038/nature07209.
59. Compton T, Nowlin DM, Cooper NR. 1993. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 193:834-841. http://dx.doi.org/10.1006/viro.1993.1192.
60. Backovic M, Longnecker R, Jardetzky TS. 2009. Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. Proc Natl Acad Sci USA 106:2880-2885. http://dx.doi.org/10.1073/pnas.0810530106.
61. Heldwein EE, Krummenacher C. 2008. Entry of herpesviruses into mammalian cells. Cell Mol Life Sci 65:1653-1668. http://dx.doi.org/10.1007/s00018-008-7570-z.
62. Backovic M, Jardetzky TS. 2011. Class III viral membrane fusion proteins. Adv Exp Med Biol 714:91-101. http://dx.doi.org/10.1007/978-94-007-0782-5_3.
63. Vitu E, Sharma S, Stampfer SD, Heldwein EE. 2013. Extensive mutagenesis of the HSV-1 gB ectodomain reveals remarkable stability of its postfusion form. J Mol Biol 425:2056-2071. http://dx.doi.org/10.1016/j.jmb.2013.03.001.
64. Stampfer SD, Lou H, Cohen GH, Eisenberg RJ, Heldwein EE. 2010. Structural basis of local, pH-dependent conformational changes in glycoprotein B from herpes simplex virus type 1. J Virol 84:12924-12933. http://dx.doi.org/10.1128/JVI.01750-10.
65. Atanasiu D, Whitbeck JC, de Leon MP, Lou H, Hannah BP, Cohen GH, Eisenberg RJ. 2010. Bimolecular complementation defines functional regions of herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. J Virol 84:3825-3834. http://dx.doi.org/10.1128/JVI.02687-09.
66. Fouts AE, Comps-Agrar L, Stengel KF, Ellerman D, Schoeffler AJ, Warming S, Eaton DL, Feierbach B. 2014. Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc Natl Acad Sci USA 111:8209-8214. http://dx.doi.org/10.1073/pnas.1404653111.
67. Plate AE, Reimer JJ, Jardetzky TS, Longnecker R. 2011. Mapping regions of Epstein-Barr virus (EBV) glycoprotein B (gB) important for fusion function with gH/gL. Virology 413:26-38. http://dx.doi.org/10.1016/j.virol.2010.12.006.